BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 8776605)

  • 41. Use of cholesterol and soluble tumour markers CEA and syndecan-2 in pleural effusions in cases of inconclusive cytology.
    Gulyas M; Fillinger J; Kaposi AD; Molnar M
    J Clin Pathol; 2019 Aug; 72(8):529-535. PubMed ID: 31028099
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Evaluation of tissue polypeptide specific antigen, CYFRA 21-1, and carcinoembryonic antigen in nonsmall cell lung carcinoma: does the combined use of cytokeratin markers give any additional information?
    Nisman B; Lafair J; Heching N; Lyass O; Baras M; Peretz T; Barak V
    Cancer; 1998 May; 82(10):1850-9. PubMed ID: 9587116
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Diagnostic value of CEA in pleural fluid for differential diagnosis of benign and malign pleural effusion.
    Radjenovic-Petkovic T; Pejcic T; Nastasijević-Borovac D; Rancic M; Radojkovic D; Radojkovic M; Djordjevic I
    Med Arh; 2009; 63(3):141-2. PubMed ID: 20088159
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Diagnostic significance of the tumor markers CEA, SCC and NSE in serum and bronchoalveolar lavage].
    von Eiff M; Koch O; Appelhans N; Roos N; van de Loo J
    Pneumologie; 1990 Feb; 44 Suppl 1():462-4. PubMed ID: 2164198
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [The value of B7-H4 and carcinoembryonic antigen in diagnosing the benign and malignant pleural effusion].
    Wei F; Wei Y; Li LF; Li GL; Wang GJ
    Zhonghua Zhong Liu Za Zhi; 2017 Jul; 39(7):524-527. PubMed ID: 28728299
    [No Abstract]   [Full Text] [Related]  

  • 46. [Diagnostic value of CEA assay combined with CA50 in malignant and benign effusion].
    Xu WB
    Zhonghua Jie He He Hu Xi Za Zhi; 1988 Dec; 11(6):327-9, 384. PubMed ID: 3250750
    [No Abstract]   [Full Text] [Related]  

  • 47. Clinical value of CYFRA 21.1, carcinoembryonic antigen, neurone-specific enolase, tissue polypeptide specific antigen and tissue polypeptide antigen in the diagnosis of lung cancer.
    Bates J; Rutherford R; Divilly M; Finn J; Grimes H; O'Muircheartaigh I; Gilmartin JJ
    Eur Respir J; 1997 Nov; 10(11):2535-8. PubMed ID: 9426091
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Utility of the serum tumor markers: CYFRA 21.1, carcinoembryonic antigen (CEA), and squamous cell carcinoma antigen (SCC) in squamous cell lung cancer.
    Tas F; Aydiner A; Topuz E; Yasasever V; Karadeniz A; Saip P
    J Exp Clin Cancer Res; 2000 Dec; 19(4):477-81. PubMed ID: 11277326
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cytokeratin 19 fragment CYFRA 21-1 compared with carcinoembryonic antigen, squamous cell carcinoma antigen and neuron-specific enolase in lung cancer. Results of an international multicentre study.
    Ebert W; Dienemann H; Fateh-Moghadam A; Scheulen M; Konietzko N; Schleich T; Bombardieri E
    Eur J Clin Chem Clin Biochem; 1994 Mar; 32(3):189-99. PubMed ID: 7518259
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The diagnostic value of the combination of carcinoembryonic antigen, squamous cell carcinoma-related antigen, CYFRA 21-1, neuron-specific enolase, tissue polypeptide antigen, and progastrin-releasing peptide in small cell lung cancer discrimination.
    Chen Z; Liu X; Shang X; Qi K; Zhang S
    Int J Biol Markers; 2021 Dec; 36(4):36-44. PubMed ID: 34709098
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Evaluation of squamous cell carcinoma antigen as a new marker for lung cancer.
    Body JJ; Sculier JP; Raymakers N; Paesmans M; Ravez P; Libert P; Richez M; Dabouis G; Lacroix H; Bureau G
    Cancer; 1990 Apr; 65(7):1552-6. PubMed ID: 2311066
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Tissue polypeptide antigen (TPA) in pleural effusions.
    Parazzi F; Faravelli B; Gallo L; Nosenzo M; Razzetti A; Barone D; Bandelloni R; D'Amore E
    Tumori; 1987 Feb; 73(1):33-6. PubMed ID: 2435037
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Value of CEA and SCC-Ag in bronchoalveolar lavage (BAL) and serum of patients with lung carcinoma.
    Nikliński J; Chyczewska E; Furman M; Kowal E; Kozłowski M
    Neoplasma; 1992; 39(5):283-5. PubMed ID: 1331827
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Lung surfactant protein-A and carcinoembryonic antigen in pleural effusions due to lung adenocarcinoma and malignant mesothelioma.
    Shijubo N; Honda Y; Fujishima T; Takahashi H; Kodama T; Kuroki Y; Akino T; Abe S
    Eur Respir J; 1995 Mar; 8(3):403-6. PubMed ID: 7789485
    [TBL] [Abstract][Full Text] [Related]  

  • 55. New approaches in the diagnostic procedure of malignant pleural effusions.
    Terracciano D; Di Carlo A; Papa P; Cicalese M; Maietta P; Cecere C; Mariano A; Macchia V
    Oncol Rep; 2004 Jul; 12(1):79-83. PubMed ID: 15201963
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Reactive oxygen species modulator 1 (Romo1) as a novel diagnostic marker for lung cancer-related malignant effusion.
    Lee SH; Park MJ; Choi SI; Lee EJ; Lee SY; In KH
    Medicine (Baltimore); 2017 Jan; 96(4):e5975. PubMed ID: 28121949
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Diagnostic value of CA 549 in pleural fluid. Comparison with CEA, CA 15.3 and CA 72.4.
    Villena V; López-Encuentra A; Echave-Sustaeta J; Martín-Escribano P; Ortuño-de-Solo B; Estenoz-Alfaro J
    Lung Cancer; 2003 Jun; 40(3):289-94. PubMed ID: 12781427
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Diagnostic value of tumor markers for lung adenocarcinoma-associated malignant pleural effusion: a validation study and meta-analysis.
    Feng M; Zhu J; Liang L; Zeng N; Wu Y; Wan C; Shen Y; Wen F
    Int J Clin Oncol; 2017 Apr; 22(2):283-290. PubMed ID: 27990560
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Diagnostic potential of carcinoembryonic antigen and ferritine in tuberculous and malignant pleural effusion.
    Loncar R; Ostojic L; Tabakovic-Loncar V; Roguljić A
    Tumori; 1995; 81(6):440-4. PubMed ID: 8804473
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Quantitative analysis of carcinoembryonic antigen, squamous cell carcinoma antigen, CA 125, and CA 50 cytosolic content in non-small cell lung cancer.
    Picardo AL; Torres AJ; Maestro M; Ortega D; Garcia-Asenjo JA; Mugüerza JM; Hernando F; Diez M; Balibrea JL
    Cancer; 1994 May; 73(9):2305-11. PubMed ID: 8168034
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.